Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Tarek A Yousry(National Hospital for Neurology and Neurosurgery), David B. Clifford(Washington University in St. Louis), Jean Hou(Cedars-Sinai Medical Center), Hans Rolf Jäger(National Hospital for Neurology and Neurosurgery), Ernst‐Wilhelm Radue, Nicole Mueller‐Lenke(Oxford Instruments (United Kingdom)), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Blanche Curfman, Eugene O. Major, Steven H. Fischer(National Institutes of Health Clinical Center), Gary A. Fahle(National Institutes of Health Clinical Center), Caroline F. Ryschkewitsch, Katherine Miszkiel(National Hospital for Neurology and Neurosurgery), Esther Sánchez(Vrije Universiteit Amsterdam)
Cited by 792
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k